Eye2Gene

Identification of inherited retinal diseases.

optometrist with pateint

Eye2Gene is an AI-powered platform combining imaging and genomics to support the identification of causative genes in inherited retinal diseases. 

By improving diagnostic accuracy, the platform enables clinicians and researchers to make more informed decisions and supports patients in accessing appropriate care pathways and participating in relevant clinical trials for new therapies, while also supporting the development of new treatments.

The spinout is based on research led by Dr Nikolas Pontikos and Dr William Woof at the UCL Institute of Ophthalmology.

The Eye2Gene journey so far:

  • 2026: Eye2Gene is founded

 

Team

Dr Nikolas Pontikos

Co-founder and CEO

Associate Professor at the Institute of Ophthalmology, working at intersection of genetics, imaging and text data to develop decision support systems for precision diagnosis, prognosis and treatment.

Dr William Woof, Co-founder and Chief AI Officer

Dr. Mark Fisher

Associate Director

Global Business School for Health

Dr Fisher is responsible for the BioPharm patent portfolio and strategic business support. He brings more than 30 years' experience in life sciences and healthcare licensing and company development.